# OnCo record nct05645107 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct05645107/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct05645107", "NCT05645107" ;
  schema:name "A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma"@en ;
  schema:alternateName "EXCELL"@en ;
  schema:description "A phase 3 trial of Xembify in chronic lymphocytic leukaemia and non-Hodgkin lymphoma, run by Grifols Therapeutics LLC, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct05645107/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05645107> ;
  onco:status "recruiting" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2022-12-26" ;
  onco:cancers <https://onco.cc/cancers/cll/>, <https://onco.cc/cancers/non-hodgkin-lymphoma/> ;
  onco:companies <https://onco.cc/companies/grifols/> .